Acetyl-11-Keto-Beta-Boswellic Acid Has Therapeutic Benefits for NAFLD Rat Models That Were Given a High Fructose Diet by Ameliorating Hepatic Inflammation and Lipid Metabolism.
AMP-activated protein kinase (AMPK)
Acetyl-11-keto-beta-boswellic acid (AKBA)
Inflammasome
Non-alcoholic fatty liver disease (NAFLD)
Peroxisome proliferator-activated receptor gamma (PPAR-ϒ)
Journal
Inflammation
ISSN: 1573-2576
Titre abrégé: Inflammation
Pays: United States
ID NLM: 7600105
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
26
01
2023
accepted:
05
06
2023
revised:
31
05
2023
medline:
12
10
2023
pubmed:
13
6
2023
entrez:
13
6
2023
Statut:
ppublish
Résumé
Acetyl-11-keto-beta-boswellic acid (AKBA), a potent anti-inflammatory compound purified from Boswellia species, was investigated in a preclinical study for its potential in preventing and treating non-alcoholic fatty liver disease (NAFLD), the most common chronic inflammatory liver disorder. The study involved thirty-six male Wistar rats, equally divided into prevention and treatment groups. In the prevention group, rats were given a high fructose diet (HFrD) and treated with AKBA for 6 weeks, while in the treatment group, rats were fed HFrD for 6 weeks and then given a normal diet with AKBA for 2 weeks. At the end of the study, various parameters were analyzed including liver tissues and serum levels of insulin, leptin, adiponectin, monocyte chemoattractant protein-1 (MCP-1), transforming growth factor beta (TGF-β), interferon gamma (INF-ϒ), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α). Additionally, the expression levels of genes related to the inflammasome complex and peroxisome proliferator-activated receptor gamma (PPAR-ϒ), as well as the levels of phosphorylated and non-phosphorylated AMP-activated protein kinase alpha-1 (AMPK-α1) protein, were measured. The results showed that AKBA improved NAFLD-related serum parameters and inflammatory markers and suppressed PPAR-ϒ and inflammasome complex-related genes involved in hepatic steatosis in both groups. Additionally, AKBA prevented the reduction of the active and inactive forms of AMPK-α1 in the prevention group, which is a cellular energy regulator that helps suppress NAFLD progression. In conclusion, AKBA has a beneficial effect on preventing and avoiding the progression of NAFLD by preserving lipid metabolism, improving hepatic steatosis, and suppressing liver inflammation.
Identifiants
pubmed: 37310644
doi: 10.1007/s10753-023-01853-y
pii: 10.1007/s10753-023-01853-y
doi:
Substances chimiques
acetyl-11-ketoboswellic acid
0
AMP-Activated Protein Kinases
EC 2.7.11.31
Inflammasomes
0
Fructose
30237-26-4
Peroxisome Proliferator-Activated Receptors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1966-1980Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Younossi, Z.M., A.B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, and M. Wymer. 2016. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64: 73–84.
pubmed: 26707365
Lee, Y.A., and S.L. Friedman. 2022. Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies. Journal of Internal Medicine 291: 11–31.
pubmed: 34564899
Barbieri, E., N. Santoro, G.R. and Umano. 2023. Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity. Frontiers in Endocrinology 14.
Stefan, N., H.-U. Häring, and K. Cusi. 2019. Non-alcoholic fatty liver disease: Causes, diagnosis, cardiometabolic consequences, and treatment strategies. The lancet Diabetes & endocrinology 7: 313–324.
He, L., G.S. Babar, J.M. Redel, S.L. Young, C.E. Chagas, W.V. Moore, and Y. Yan. 2021. Fructose intake: metabolism and role in diseases. In Sugar Intake-Risks and Benefits and the Global Diabetes Epidemic: IntechOpen.
Pereira, R.M., J.D. Botezelli, K.C. da Cruz Rodrigues, R.A. Mekary, D.E. Cintra, J.R. Pauli, A.S.R. Da Silva, E.R. Ropelle, and L.P. De Moura. 2017. Fructose consumption in the development of obesity and the effects of different protocols of physical exercise on the hepatic metabolism. Nutrients 9: 405.
pubmed: 28425939
pmcid: 5409744
Jegatheesan, P., and J.P. De Bandt. 2017. Fructose and NAFLD: The multifaceted aspects of fructose metabolism. Nutrients 9: 230.
pubmed: 28273805
pmcid: 5372893
Federico, A., V. Rosato, M. Masarone, P. Torre, M. Dallio, M. Romeo, and M. Persico. 2021. The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights. Nutrients 13: 1314.
pubmed: 33923525
pmcid: 8074203
Liu, Y., H. Lin, L. Jiang, Q. Shang, L. Yin, J.D. Lin, W.-S. Wu, and L. Rui. 2020. Hepatic Slug epigenetically promotes liver lipogenesis, fatty liver disease, and type 2 diabetes. The Journal of Clinical Investigation 130: 2992–3004.
pubmed: 32365055
pmcid: 7260003
Baboota, R.K., R. Spinelli, M.C. Erlandsson, B.B. Brandao, M. Lino, H. Yang, A. Mardinoglu, M.I. Bokarewa, J. Boucher, and C.R. Kahn. 2022. Chronic hyperinsulinemia promotes human hepatocyte senescence. Molecular Metabolism 64: 101558.
pubmed: 35872305
pmcid: 9364104
Zhang, A.M., E.A. Wellberg, J.L. Kopp, and J.D. Johnson. 2021. Hyperinsulinemia in obesity, inflammation, and cancer. Diabetes & metabolism journal 45: 285–311.
Jung, U.J., and M.-S. Choi. 2014. Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. International journal of molecular sciences 15: 6184–6223.
pubmed: 24733068
pmcid: 4013623
Longo, M., F. Zatterale, J. Naderi, L. Parrillo, P. Formisano, G.A. Raciti, F. Beguinot, and C. Miele. 2019. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. International journal of molecular sciences 20: 2358.
pubmed: 31085992
pmcid: 6539070
Petrescu, M., S.I. Vlaicu, L. Ciumărnean, M.V. Milaciu, C. Mărginean, M. Florea, ȘC. Vesa, and M. Popa. 2022. Chronic inflammation—a link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue. Medicina 58: 641.
pubmed: 35630058
pmcid: 9147364
Paradies, G., V. Paradies, F.M. Ruggiero, and G. Petrosillo. 2014. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World journal of gastroenterology: WJG 20: 14205.
pubmed: 25339807
pmcid: 4202349
Yu, L., W. Hong, S. Lu, Y. Li, Y. Guan, X. Weng, and Z. Feng. 2022. The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: Therapeutic targets and treatment. Frontiers in Pharmacology 13: 682.
Knorr, J., A. Wree, F. Tacke, A.E. Feldstein. 2020. The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis. Presented at Seminars in liver disease.
Gehrke, N., and J.M. Schattenberg. 2020. Metabolic inflammation—a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease? Gastroenterology 158 (1929–47): e6.
Smith, B.K., K. Marcinko, E.M. Desjardins, J.S. Lally, R.J. Ford, and G.R. Steinberg. 2016. Treatment of nonalcoholic fatty liver disease: Role of AMPK. American Journal of Physiology-Endocrinology and Metabolism 311: E730–E740.
pubmed: 27577854
Zhao, P., and A.R. Saltiel. 2020. From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases. Journal of Biological Chemistry 295: 12279–12289.
pubmed: 32651233
pmcid: 7443502
Fang, C., J. Pan, N. Qu, Y. Lei, J. Han, J. Zhang, D. Han. 2022. The AMPK pathway in fatty liver disease. Frontiers in Physiology 13.
Liss, K.H., and B.N. Finck. 2017. PPARs and nonalcoholic fatty liver disease. Biochimie 136: 65–74.
pubmed: 27916647
Ducheix, S., A. Montagner, V. Theodorou, L. Ferrier, and H. Guillou. 2013. The liver X receptor: A master regulator of the gut–liver axis and a target for non alcoholic fatty liver disease. Biochemical pharmacology 86: 96–105.
pubmed: 23542537
Fleischman, M.W., M. Budoff, I. Zeb, D. Li, and T. Foster. 2014. NAFLD prevalence differs among hispanic subgroups: The Multi-Ethnic Study of Atherosclerosis. World journal of gastroenterology: WJG 20: 4987.
pubmed: 24803810
pmcid: 4009531
Xu, Y., W. Guo, C. Zhang, F. Chen, H.Y. Tan, S. Li, N. Wang, and Y. Feng. 2020. Herbal medicine in the treatment of non-alcoholic fatty liver diseases-efficacy, action mechanism, and clinical application. Frontiers in Pharmacology 11: 601.
pubmed: 32477116
pmcid: 7235193
Tian, Y., J. Ma, W. Wang, L. Zhang, J. Xu, K. Wang, and D. Li. 2016. Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver. Molecular and cellular biochemistry 422: 75–84.
pubmed: 27613163
Jiang, J., L. Yan, Z. Shi, L. Wang, L. Shan, and T. Efferth. 2019. Hepatoprotective and anti-inflammatory effects of total flavonoids of Qu Zhi Ke (peel of Citrus changshan-huyou) on non-alcoholic fatty liver disease in rats via modulation of NF-κB and MAPKs. Phytomedicine 64: 153082.
pubmed: 31541796
Roy, N.K., D. Parama, K. Banik, D. Bordoloi, A.K. Devi, K.K. Thakur, G. Padmavathi, M. Shakibaei, L. Fan, and G. Sethi. 2019. An update on pharmacological potential of boswellic acids against chronic diseases. International journal of molecular sciences 20: 4101.
pubmed: 31443458
pmcid: 6747466
Sharma, T., and S. Jana. 2020. Boswellic acids as natural anticancer medicine: Precious gift to humankind. Journal of Herbal Medicine 20: 100313.
Siddiqui, A., Z. Shah, R.N. Jahan, I. Othman, and Y. Kumari. 2021. Mechanistic role of boswellic acids in Alzheimer’s disease: Emphasis on anti-inflammatory properties. Biomedicine & Pharmacotherapy 144: 112250.
Kawasaki, T., K. Igarashi, T. Koeda, K. Sugimoto, K. Nakagawa, S. Hayashi, R. Yamaji, H. Inui, T. Fukusato, and T. Yamanouchi. 2009. Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. The Journal of nutrition 139: 2067–2071.
pubmed: 19776184
Upadhayay, S., S. Mehan, A. Prajapati, P. Sethi, M. Suri, A. Zawawi, M.N. Almashjary, and S. Tabrez. 2022. Nrf2/HO-1 signaling stimulation through acetyl-11-keto-beta-boswellic acid (AKBA) provides neuroprotection in ethidium bromide-induced experimental model of multiple sclerosis. Genes 13: 1324.
pubmed: 35893061
pmcid: 9331916
Li, W., J. Liu, W. Fu, X. Zheng, L. Ren, S. Liu, J. Wang, T. Ji, and G. Du. 2018. 3-O-acetyl-11-keto-β-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase. Journal of Experimental & Clinical Cancer Research 37: 1–15.
Meratan, A.A., and M. Nemat-Gorgani. 2012. Mitochondrial membrane permeabilization upon interaction with lysozyme fibrillation products: role of mitochondrial heterogeneity. Biochimica et Biophysica Acta (BBA)-Biomembranes 1818: 2149–57.
Sottacasa, G., B. Kuylenstierna, L. Ernster, and A. Bergstrand. 1967. Separation and some enzymatic properties of the inner and outer membrane of rat liver mitochondria. Methods in Enzymology 10: 457.
Müller-Kraft, G., and W. Babel. 1990. [53] Citrate synthases from methylotrophs. Methods in enzymology 188: 350–354.
Xu, J., J. Shen, R. Yuan, B. Jia, Y. Zhang, S. Wang, Y. Zhang, M. Liu, T. Wang. 2021. Mitochondrial targeting therapeutics: promising role of natural products in non-alcoholic fatty liver disease. Frontiers in Pharmacology 12.
Minj, E., S. Upadhayay, and S. Mehan. 2021. Nrf2/HO-1 signaling activator acetyl-11-keto-beta boswellic acid (AKBA)-mediated neuroprotection in methyl mercury-induced experimental model of ALS. Neurochemical research 46: 2867–2884.
pubmed: 34075522
Marefati, N., F. Beheshti, S. Memarpour, R. Bayat, M.N. Shafei, H.R. Sadeghnia, H. Ghazavi, and M. Hosseini. 2020. The effects of acetyl-11-keto-β-boswellic acid on brain cytokines and memory impairment induced by lipopolysaccharide in rats. Cytokine 131: 155107.
pubmed: 32380425
Ahmed, M.A., A.A. Ahmed, and E.M. El Morsy. 2020. Acetyl-11-keto-β-boswellic acid prevents testicular torsion/detorsion injury in rats by modulating 5-LOX/LTB4 and p38-MAPK/JNK/Bax/Caspase-3 pathways. Life Sciences 260: 118472.
pubmed: 32971106
Moussaieff, A., and R. Mechoulam. 2009. Boswellia resin: From religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. Journal of Pharmacy and Pharmacology 61: 1281–1293.
Bini Araba, A., N. Ur Rehman, A. Al-Araimi, S. Al-Hashmi, S. Al-Shidhani, R. Csuk, H. Hussain, A. Al-Harrasi, and F. Zadjali. 2021. New derivatives of 11-keto-β-boswellic acid (KBA) induce apoptosis in breast and prostate cancers cells. Natural Product Research 35: 707–716.
pubmed: 30931626
Taherzadeh, D., V. Baradaran Rahimi, H. Amiri, S. Ehtiati, R. Yahyazadeh, S.I. Hashemy, and V.R. Askari. 2022. Acetyl-11-Keto-β-Boswellic acid (AKBA) prevents lipopolysaccharide-induced inflammation and cytotoxicity on H9C2 cells. Evidence-based Complementary and Alternative Medicine 2022.
Nassir, F., and J.A. Ibdah. 2014. Role of mitochondria in nonalcoholic fatty liver disease. International journal of molecular sciences 15: 8713–8742.
pubmed: 24837835
pmcid: 4057755
Monzio Compagnoni, G., A. Di Fonzo, S. Corti, G.P. Comi, N. Bresolin, and E. Masliah. 2020. The role of mitochondria in neurodegenerative diseases: The lesson from Alzheimer’s disease and Parkinson’s disease. Molecular neurobiology 57: 2959–2980.
pubmed: 32445085
Kang, W., M. Suzuki, T. Saito, and K. Miyado. 2021. Emerging role of TCA cycle-related enzymes in human diseases. International Journal of Molecular Sciences 22: 13057.
pubmed: 34884868
pmcid: 8657694
Santamarina, A.B., M. Carvalho-Silva, L.M. Gomes, M.H. Okuda, A.A. Santana, E.L. Streck, M. Seelaender, C.M.O. do Nascimento, E.B. Ribeiro, and F.S. Lira. 2015. Decaffeinated green tea extract rich in epigallocatechin-3-gallate prevents fatty liver disease by increased activities of mitochondrial respiratory chain complexes in diet-induced obesity mice. The Journal of Nutritional Biochemistry 26: 1348–1356.
pubmed: 26300331
Ferramosca, A., A. Conte, and V. Zara. 2015. Krill oil ameliorates mitochondrial dysfunctions in rats treated with high-fat diet. BioMed Research International 2015.
Ma, Y., M. Gao, and D. Liu. 2016. Alternating diet as a preventive and therapeutic intervention for high fat diet-induced metabolic disorder. Scientific reports 6: 1–14.
Skat-Rørdam, J., D. Højland Ipsen, J. Lykkesfeldt, and P. Tveden-Nyborg. 2019. A role of peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease. Basic & clinical pharmacology & toxicology 124: 528–537.
Zhang, Y.-L., A. Hernandez-Ono, P. Siri, S. Weisberg, D. Conlon, M.J. Graham, R.M. Crooke, L.-S. Huang, and H.N. Ginsberg. 2006. Aberrant hepatic expression of PPARγ2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. Journal of Biological Chemistry 281: 37603–37615.
pubmed: 16971390
Awad, A.S., E.N. Abd Al Haleem, W.M. El-Bakly, and M.A. Sherief. 2016. Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis. Naunyn-Schmiedeberg’s archives of pharmacology 389: 381–391.
pubmed: 26753695
Chyau, C.-C., H.-F. Wang, W.-J. Zhang, C.-C. Chen, S.-H. Huang, C.-C. Chang, and R.Y. Peng. 2020. Antrodan alleviates high-fat and high-fructose diet-induced fatty liver disease in C57BL/6 mice model via AMPK/Sirt1/SREBP-1c/PPARγ pathway. International Journal of Molecular Sciences 21: 360.
pubmed: 31935815
pmcid: 6981486
Gao, H., T. Guan, C. Li, G. Zuo, J. Yamahara, J. Wang, and Y. Li. 2012. Treatment with ginger ameliorates fructose-induced Fatty liver and hypertriglyceridemia in rats: modulation of the hepatic carbohydrate response element-binding protein-mediated pathway. Evidence-Based Complementary and Alternative Medicine 2012.
Li, X., Z. Xu, S. Wang, H. Guo, S. Dong, T. Wang, L. Zhang, and Z. Jiang. 2016. Emodin ameliorates hepatic steatosis through endoplasmic reticulum–stress sterol regulatory element-binding protein 1c pathway in liquid fructose-feeding rats. Hepatology Research 46: E105–E117.
pubmed: 26031413
Trepiana, J., I. Milton-Laskibar, S. Gómez-Zorita, I. Eseberri, M. González, A. Fernández-Quintela, and M.P. Portillo. 2018. Involvement of 5′ AMP-activated protein kinase (AMPK) in the effects of resveratrol on liver steatosis. International journal of molecular sciences 19: 3473.
pubmed: 30400630
pmcid: 6274712
Boudaba, N., A. Marion, C. Huet, R. Pierre, B. Viollet, and M. Foretz. 2018. AMPK re-activation suppresses hepatic steatosis but its downregulation does not promote fatty liver development. eBioMedicine 28: 194–209.
pubmed: 29343420
pmcid: 5835560
Shen, T., B. Xu, T. Lei, L. Chen, C. Zhang, and Z. Ni. 2018. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. Experimental and therapeutic medicine 16: 3121–3128.
pubmed: 30214535
pmcid: 6125831
ALTamimi JZ, Alshammari GM, AlFaris NA, Alagal RI, Aljabryn DH, Albekairi NA, Alkhateeb MA, and Yahya MA. 2022. Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK. Pharmaceutical Biology 60: 25–37.
Shiwa, M., M. Yoneda, H. Okubo, H. Ohno, K. Kobuke, Y. Monzen, R. Kishimoto, Y. Nakatsu, T. Asano, and N. Kohno. 2015. Distinct time course of the decrease in hepatic AMP-activated protein kinase and Akt phosphorylation in mice fed a high fat diet. PLoS ONE 10: e0135554.
pubmed: 26266809
pmcid: 4534138
Guo, H., J.B. Callaway, and J.P. Ting. 2015. Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nature medicine 21: 677–687.
pubmed: 26121197
pmcid: 4519035
Gong, Y., X. Jiang, S. Yang, Y. Huang, J. Hong, Y. Ma, X. Fang, Y. Fang, and J. Wu. 2022. The biological activity of 3-O-acetyl-11-keto-β-boswellic acid in nervous system diseases. NeuroMolecular Medicine 1–11.
Majeed, M., K. Nagabhushanam, L. Lawrence, R. Nallathambi, V. Thiyagarajan, and L. Mundkur. 2021. Boswellia serrata extract containing 30% 3-acetyl-11-keto-boswellic acid attenuates inflammatory mediators and preserves extracellular matrix in collagen-induced arthritis. Frontiers in Physiology 1578.
Suther, C., L. Devon, L. Daddi, A. Matson, H. Panier, H. Yuan, K. Saar, S. Bokoliya, Y. Dorsett, and D.A. Sela. 2022. Dietary Indian frankincense (Boswellia serrata) ameliorates murine allergic asthma through modulation of the gut microbiome. Journal of Functional Foods 97: 105249.